Benzinga | Jul 21, 2021 08:52AM EDT

Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod

* The European Commission (EC) has approved Merck & Co Inc's (NYSE:MRK) soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat).

* Verquvo (2.5 mg, 5 mg, and 10 mg) is indicated to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy.

* Merck has the commercial rights to Verquvo in the U.S., and Bayer AG (OTC:BAYRY) has the exclusive commercial rights in the rest of the world.

* In January, the FDA approved Verquvo.

* Price Action: MRK shares are up 0.42% at $76.49 during the premarket session on the last check Wednesday.

* Related content: Benzinga's Full FDA Calendar.